Skip to content
Screener

Opko Health OPK Stock-Based Comp

Stock-Based Comp at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
$23M+9.5%
Regenxbio logo
RegenxbioRGNX
$9.05M+4.6%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$3.46M+4.0%
PTH
Pelthos TherapeuticsPTHS
$1.91M+293%
Exelixis logo
ExelixisEXEL
$32.56M-9.7%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$17.16M+54.2%

Other financials

Income statement

See full
Revenue$163.6M+4.3%
Gross profit$80.0M+62.0%
Operating income-$7.0M+88.4%
Net income-$8.4M+94.3%
EPS (diluted)-$0.01+94.7%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$49.9M-7.5%
Total equity$1.2B-8.7%
Total assets$1.8B-7.3%

Cash flow

See full
Operating cash flow-$43.5M+47.9%
CapEx$3.0M-8.5%
Free cash flow-$46.5M+46.4%

Valuation

See full
Market cap$985.15M-2.3%
P/S1.7×+0.2×

Profitability

See full
Gross margin40.8%+8.1pp
Operating margin-8.2%-3.5pp
Net margin-12.4%-4.3pp
FCF margin-22.8%-6.7pp

Returns & leverage

See full
Return on equity-5.9%-2.1pp
Debt / equity0.0×
Current ratio3.3×-0.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Opko Health’s 10-Q, filed July 27, 2026.

Filed
Jul 27, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-318090

Equity-based compensation. We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award. For the three and six months ended June 30, 2026, we recorded $2.2 million and $5.0 million, respectively, of equity-based compensation expense. For the three and six months ended June 30, 2025, we recorded $2.2 million and $4.8 million, respectively, of equity-based compensation expense.

Item 1. Financial Statements

FAQ

What is Opko Health's stock-based comp?
Opko Health (OPK) reported stock-based comp of $2.2M in Q2 2026.
How has Opko Health's stock-based comp changed year-over-year?
Opko Health's stock-based comp decreased by 0.0% year-over-year, from $2.2M to $2.2M.
What is the long-term trend for Opko Health's stock-based comp?
Over 4 years (2021 to 2025), Opko Health's stock-based comp has grown at a -5.8% compound annual growth rate (CAGR), from $13.63M to $10.73M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Opko Health's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude